<i>In Vitro</i> Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program-Reference-Cited by-同舟云学术

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

Published:2023-01-24 Issue:1 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Karlowsky James A.¹²,Hackel Meredith A.¹^ORCID,Wise Mark G.¹,Six David A.³,Uehara Tsuyoshi³,Daigle Denis M.³^ORCID,Cusick Susan M.³,Pevear Daniel C.³,Moeck Greg³,Sahm Daniel F.¹

Affiliation:

1. IHMA, Schaumburg, Illinois, USA

2. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

3. Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA

Abstract

Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n = 13,731) and Pseudomonas aeruginosa ( n = 4,619) isolates cultured from infected patients attending hospitals in 56 countries.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Wellcome Trust

U.S. Department of Health and Human Services

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01281-22

Reference42 articles.

1. Epidemiology of β-Lactamase-Producing Pathogens

2. Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program

3. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017

4. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013–17

5. World Health Organization. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reviewing novel treatment options for carbapenem-resistant Enterobacterales;Expert Review of Anti-infective Therapy;2024-01-05

2. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?;European Journal of Clinical Microbiology & Infectious Diseases;2023-12-14

3. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain;European Journal of Clinical Microbiology & Infectious Diseases;2023-12-02

4. Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States;Antimicrobial Agents and Chemotherapy;2023-11-15

5. In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales;Antimicrobial Agents and Chemotherapy;2023-11-15